



Notification HUM-6777; HUM-6781; HUM-6783; HUM-6785:

Category

HCPCS - Drugs & Biologicals

Topic

Injection, bendamustine hydrochloride, 1 mg

What is changing? / Change Description:

<u>HUM-ID</u>	<u>Topic</u>	<u>Change Description</u>
<u>6777</u>	<u>Injection, bendamustine hydrochloride, 1 mg</u>	<u>For provider specialties other than pharmacy, we limit reimbursement of charges for HCPCS code J9036, J9056, J9058 or J9059 to no more than 648 units every 4 weeks if submitted with a diagnosis of systemic light chain amyloidosis.</u>
<u>6781</u>	<u>Injection, bendamustine hydrochloride, 1 mg</u>	<u>For provider specialties other than pharmacy, we limit reimbursement of charges for HCPCS code J9036, J9056, J9058 or J9059 to no more than 1,296 units every 6 weeks if submitted with a diagnosis of B-cell lymphoma.</u>
<u>6783</u>	<u>Injection, bendamustine hydrochloride, 1 mg</u>	<u>For provider specialties other than pharmacy, we limit reimbursement of charges for HCPCS code J9036, J9056, J9058 or J9059 to no more than 5,184 units every 26 weeks if submitted with one of the following diagnoses:• Hodgkin's lymphoma (classic) (adult)• Hodgkin's lymphoma (classic) (pediatric)• Systemic light chain amyloidosis• T-cell lymphoma</u>
<u>6785</u>	<u>Injection, bendamustine hydrochloride, 1 mg</u>	<u>For provider specialties other than home infusion therapy, we limit reimbursement of charges for HCPCS code J9036, J9056, J9058 or J9059 to no more than 18 visits every 26 weeks if submitted with a diagnosis of breast cancer.</u>

Language

English

Impacted Products

Medicaid – Louisiana

Why is Humana making this change? / Change Reason:

<u>HUM-ID</u>	<u>Topic</u>	<u>Change Reason</u>
<u>6777</u>	<u>Injection, bendamustine hydrochloride, 1 mg</u>	<u>The above limitations were established by the FDA-approved package insert and prescribing information or the pharmaceutical compendia. Note: The limitations described above are based on maximum dosages established in milligrams. If any units are denied, the provider may dispute the decision through the appropriate process. The provider may submit information, including medical notes showing the patient's body surface area, that substantiates the medical necessity of the additional units.</u>
<u>6781</u>	<u>Injection, bendamustine hydrochloride, 1 mg</u>	<u>The above limitations were established by the FDA-approved package insert and prescribing information or the pharmaceutical compendia. Note: The limitations described above are based on maximum dosages established in milligrams. If any units are denied, the provider may dispute the decision through the appropriate process. The provider may submit information, including medical notes showing the patient's body surface area, that substantiates the medical necessity of the additional units.</u>
<u>6783</u>	<u>Injection, bendamustine hydrochloride, 1 mg</u>	<u>The above limitations were established by the FDA-approved package insert and prescribing information or the pharmaceutical compendia. Note: The limitations described above are based on maximum dosages established in milligrams. If any units are denied, the provider may dispute the decision through the appropriate process. The provider may submit information, including medical notes showing the patient's body surface area, that substantiates the medical necessity of the additional units.</u>
<u>6785</u>	<u>Injection, bendamustine hydrochloride, 1 mg</u>	<u>The above limitations were established by the FDA-approved package insert and prescribing information or the pharmaceutical compendia.</u>